We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+91.23%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$18.1M
Cap. Flow
+$54.1M
Cap. Flow %
7.36%
Top 10 Hldgs %
42.08%
Holding
212
New
67
Increased
34
Reduced
65
Closed
41

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$11.6M
2
TGTX icon
TG Therapeutics
TGTX
+$8.36M
3
BPMC
Blueprint Medicines
BPMC
+$7.73M
4
FBRX icon
Forte Biosciences
FBRX
+$7.25M
5
VIR icon
Vir Biotechnology
VIR
+$7.08M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$19.2M
2
ONC
BeOne Medicines Ltd
ONC
+$18M
3
SLNO
Soleno Therapeutics
SLNO
+$11.5M
4
RCUS icon
Arcus Biosciences
RCUS
+$5.97M
5
TECX
Tectonic Therapeutic
TECX
+$5.28M

Sector Composition

Rank Sector Weight
1 Healthcare 47.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
51
PUT
AnaptysBio
ANAB
$1.56B
$4.11M 0.56%
310,800
-93,500
-23% -$2.26M
MLYS icon
52
Mineralys Therapeutics
MLYS
$2.24B
$4.09M 0.56%
332,390
+152,390
+85% +$1.99M
NUVL
53
DELISTED
Nuvalent
NUVL
$4.09M 0.56%
52,216
-22
-0% -$2.06K
CRVS icon
54
CALL
Corvus Pharmaceuticals
CRVS
$1.11B
$4.04M 0.55%
754,400
+536,100
+246% +$4M
JANX icon
55
Janux Therapeutics
JANX
$925M
$4M 0.54%
+74,691
New +$3.95M
VRNA
56
DELISTED
Verona Pharma
VRNA
$3.72M 0.51%
+80,000
New +$3M
NMRA icon
57
PUT
Neumora Therapeutics
NMRA
$285M
$3.71M 0.5%
350,000
-50,000
-13% -$599K
HELP
58
Cybin Inc
HELP
$483M
$3.5M 0.48%
397,175
+29,980
+8% +$304K
ARCT icon
59
Arcturus Therapeutics
ARCT
$162M
$3.39M 0.46%
+200,000
New +$3.77M
SLNO
60
PUT
DELISTED
Soleno Therapeutics
SLNO
$3.37M 0.46%
+75,000
New +$3.89M
VRDN icon
61
CALL
Viridian Therapeutics
VRDN
$2.1B
$3.36M 0.46%
175,100
-24,900
-12% -$541K
ANAB icon
62
CALL
AnaptysBio
ANAB
$1.56B
$3.31M 0.45%
250,000
-100,000
-29% -$2.42M
LXEO icon
63
Lexeo Therapeutics
LXEO
$323M
$3.29M 0.45%
499,301
+242,085
+94% +$1.91M
ABEO icon
64
Abeona Therapeutics
ABEO
$361M
$2.97M 0.4%
533,581
-50,012
-9% -$308K
RNAM
65
CALL
DELISTED
Avidity Biosciences
RNAM
$2.91M 0.4%
+100,000
New +$4.18M
RLAY icon
66
Relay Therapeutics
RLAY
$4.12B
$2.86M 0.39%
693,308
-42
-0% -$229
RCKT icon
67
Rocket Pharmaceuticals
RCKT
$339M
$2.79M 0.38%
221,911
+24,815
+13% +$374K
PTGX icon
68
Protagonist Therapeutics
PTGX
$8.77B
$2.7M 0.37%
+70,000
New +$3.05M
CRVS icon
69
PUT
Corvus Pharmaceuticals
CRVS
$1.11B
$2.67M 0.36%
+500,000
New +$3.73M
ALGS icon
70
Aligos Therapeutics
ALGS
$26.6M
$2.56M 0.35%
+64,300
New +$1.24M
ZVRA icon
71
Zevra Therapeutics
ZVRA
$570M
$2.44M 0.33%
+292,772
New +$2.5M
XENE icon
72
Xenon Pharmaceuticals
XENE
$6.11B
$2.43M 0.33%
62,052
-45,135
-42% -$1.87M
NVAX icon
73
CALL
Novavax
NVAX
$1.2B
$2.41M 0.33%
+300,000
New +$2.89M
VTYX
74
DELISTED
Ventyx Biosciences
VTYX
$2.39M 0.33%
1,092,590
+899,943
+467% +$2.04M
TEVA icon
75
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$2.2M 0.3%
+100,000
New +$1.82M
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Ikarian Capital held 212 positions worth $735M, up 2.5% from $717M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital deployed $54.1M of net new capital in Q4 2024, opening 67 new positions and adding to 34 existing holdings. Its largest new stake was Scholar Rock: 357,185 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $19.2M trimmed.

  • Ikarian Capital's largest Q4 2024 buy was Scholar Rock: 357,185 shares worth $15.4M.
  • Ikarian Capital added most to Blueprint Medicines in Q4 2024, an estimated $7.73M increase.
  • Ikarian Capital's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $19.2M.
  • Ikarian Capital fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $18M.
  • Ikarian Capital's ten largest holdings make up 42% of its $735M portfolio in Q4 2024.
  • Ikarian Capital opened 67 new positions and closed 41 in Q4 2024.
  • Ikarian Capital's portfolio value rose 2.5% quarter-over-quarter to $735M.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.